ArticleBMC infectious diseases2019
Enterococcal periprosthetic joint infection: clinical and microbiological findings from an 8-year retrospective cohort study.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- [Antimicrobial therapy of periprosthetic joint infection : Summary of AE guidelines (2026)].Orthopadie (Heidelberg, Germany) · 2026Review
- [Antimicrobial therapy of periprosthetic joint infection : Full version of the AE guidelines (2026)].Orthopadie (Heidelberg, Germany) · 2026Review
- Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.Journal of orthopaedic surgery and research · 2026Article
- Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci.Microbiology spectrum · 2026Article
- Septic arthritis and prosthetic joint infections: microbial spectrum and evolving resistance patterns.Journal of bone and joint infection · 2026Article
- What constitutes a true polymicrobial periprosthetic joint infection? From multiple detections to organism-level causality.Frontiers in microbiology · 2026Review
- Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Rare but Risky: Orthopedic Infections by Unconventional Gram-Positive Cocci - A Case Series.Journal of orthopaedic case reports · 2025Article
- Polymicrobial Prosthetic Joint Infections: Unraveling Risk Factors and Outcomes in a Single-Center Study.Microorganisms · 2025Article
- Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.Microorganisms · 2025Review
- Insights into ecology, pathogenesis, and biofilm formation ofMicrobiology and molecular biology reviews : MMBR · 2025Review
- Article
- N-acetyl cysteine as an additive to bone cement against pathogens involved in periprosthetic joint infections.Frontiers in bioengineering and biotechnology · 2025Article
- Impact of Manual Addition of Vancomycin to Polymethylmethacrylate (PMMA) Cements.Antibiotics (Basel, Switzerland) · 2024Article
- Genotypic and phenotypic characterization ofbioRxiv : the preprint server for biology · 2024Article
- Successful Implant Retention in a Chronified Hematogenous Bilateral Periprosthetic Hip Joint Infection WithArthroplasty today · 2024Article
- Periprosthetic Joint Infection Diagnosis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Interest in the combination of antimicrobial therapy for orthopaedic device-related infections due to Enterococcus spp.Archives of orthopaedic and trauma surgery · 2023Article
- Bacterial pathogens and in-hospital mortality in revision surgery for periprosthetic joint infection of the hip and knee: analysis of 346 patients.European journal of medical research · 2023Observational
- Clinical Features and Outcomes of Enterococcal Bone and Joint Infections and Factors Associated with Treatment Failure over a 13-Year Period in a French Teaching Hospital.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundTreatment of enterococcal periprosthetic joint infections (PJI) is challenging due to non-standardized management strategies and lack of biofilm-active antibiotics. The optimal surgical and antimicrobial therapy are unknown. Therefore, we evaluated characteristics and outcome of enterococcal PJI.
methodsConsecutive patients with enterococcal PJI from two specialized orthopedic institutions were retrospectively analyzed. Both institutions are following the same diagnostic and treatment concepts. The probability of relapse-free survival was estimated using Kaplan-Meier survival curves and compared by log-rank test. Treatment success was defined by absence of relapse or persistence of PJI due to enterococci or death related to enterococcal PJI. Clinical success was defined by the infection-free status, no subsequent surgical intervention for persistent or perioperative infection after re-implantation and no PJI-related death within 3 months.
resultsIncluded were 75 enterococcal PJI episodes, involving 41 hip, 30 knee, 2 elbow and 2 shoulder prostheses. PJI occurred postoperatively in 61 episodes (81%), hematogenously in 13 (17%) and by contiguous spread in one. E. faecalis grew in 64 episodes, E. faecium in 10 and E. casseliflavus in one episode(s). Additional microorganism(s) were isolated in 38 patients (51%). Enterococci were susceptible to vancomycin in 73 of 75 isolates (97%), to daptomycin in all 75 isolates, and to fosfomycin in 21 of 22 isolates (96%). The outcome data was available for 66 patients (88%). The treatment success after 3 years was 83.7% (95% confidence interval [CI]; 76.1-96.7%) and the clinical success was 67.5% (95% CI; 57.3-80.8%). In 11 patients (17%), a new PJI episode caused by a different pathogen occurred. All failures occurred within 3 years after surgery.
conclusionAbout half of enterococcal PJI were polymicrobial infections. The treatment success was high (84%). All treatment failures occurred within the first 3 years after revision surgery. Interestingly, 17% of patients experienced a new PJI caused by another pathogen at a later stage.
trial registrationThe study was retrospectively registered with the public clinical trial identification NCT0253022 at https://www.clinicaltrials.gov on 15 July 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.